We also found a significant down-regulation in the expression of the Nrf2 downstream genes GCLM, GCLC and NQO1 in breast, prostate and kidney cancer respectively (Additional file9: Figure S8), suggesting that Nrf2 protein activity might also be reduced in these tumors. The gene discussed is GCLC; the disease is kidney cancer.